The partnership brings together Salipro’s tech for stabilising drug targets from Boehringer’s drug discovery programmes.

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of ...

Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, ...

Mankind Pharma, Alkem Laboratories, Glenmark are some of the companies to have launched, making the drug affordable to most ...

Prices of key anti-diabetic drug empagliflozin crashed by as much as 90 per cent to ₹5.5 per tablet as several pharma ...

New Delhi: In response to the proposal presented by Boehringer Ingelheim, the Subject Expert Committee (SEC) functional under ...

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.